Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > AME study results
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jul 13, 2021 1:40pm
186 Views
Post# 33536443

RE:RE:RE:RE:RE:AME study results

RE:RE:RE:RE:RE:AME study results
Edou111 wrote: Dear InthePez

As "dumb" as it might appear, I have been investing in pharma /bio stocks for more than a decade and have seen this scenario too many times...Overreacting is no good for the inflammation in your body !  Take care !


Which scenario have you seen too many times ?

The one where the share price isn't in line with the value of the company (I too have seen that many times)

OR

"Adverse events across the three doses of ATB-346 were similar to placebo, with very few serious adverse events or events leading to withdrawl of treatment.  Adjucating for patient-specific factors reflected a liver safety profile for AT-346 that was comparable to commonly prescribed NSAIDs, and substantially improved over that of acetaminophen."

OR

maybe you've referencing the potential for a lower dose than expected ... as low as 1/10 the competition's daily prescribed intake.  The Enhanced AME might have some use here.

: )



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities